Side-by-side · Research reference
5-Amino-1MQvsCartalax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongAUTO-DRAFTED8/38 cited
BAnimal-MechanisticHUMAN-REVIEWED10/32 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
Cartalax
Bioregulator Peptide · Khavinson School
SQ · Protocol Unspecified
01Mechanism of Action
Parameter
5-Amino-1MQ
Cartalax
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Feedback intact?
—
—
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
Cartalax
Frequency
Once daily, fasted
—
Lower / starter dose
50 mg / day
—
Duration
8–12 weeks per cycle
—
Form
Oral capsule
—
Timing
Morning fasted preferred
—
Half-life
Hours (estimated; no human PK published)
—
Animal model dose
—
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
Human dosing
—
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
03Metabolic / Fat Loss Evidence
Parameter
5-Amino-1MQ
Cartalax
Fat loss evidence
—
None — primary target is cartilage and bone tissue, not adipose
04Side Effects & Safety
Parameter
5-Amino-1MQ
Cartalax
GI symptoms
Mild nausea (anecdotal)
—
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
—
Cancer risk
Unclear — NNMT also studied in oncology contexts
—
Pregnancy / OB
Avoid
—
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Documented adverse effects
—
None reported in indexed animal studies
Human safety data
—
Not available in PubMed-indexed literature
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
Cartalax
- ·Unknown due to lack of human clinical trial data
Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
Cartalax
- ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
05Administration Protocol
Parameter
5-Amino-1MQ
Cartalax
1. Form
Oral capsule. No injection.
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
2. Administration
Take with water, fasted preferred.
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
3. Timing
Morning fasted.
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
4. Storage
Room temp ≤25 °C, dry place.
—
5. Caveat
Monitor B-vitamin status with chronic use.
—